Plain-English translation of NCT07245069 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a medication called dapagliflozin can protect your heart while you receive anthracycline chemotherapy for breast cancer. Some breast cancer chemotherapy drugs can damage the heart over time, but this medication has shown promise in protecting heart health in other conditions. Researchers want to find out if taking this medication daily during and after your chemotherapy can prevent or reduce heart damage.
Certain chemotherapy drugs used to treat breast cancer can weaken the heart, sometimes months or years after treatment ends. Right now, doctors don't have a proven medication to prevent this damage, so this trial is testing whether this medication could be the first effective way to protect your heart during cancer treatment.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the study medication or a placebo (inactive pill) once daily for one year, starting before or when your chemotherapy begins. You would have baseline heart and blood vessel ultrasounds, walking tests, and blood work done before starting, and these tests would be repeated during and after your chemotherapy to see how your heart is doing. Throughout the year, you would visit the research team regularly to check on your progress and report any side effects.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Slovenia